Total Payments
$446,823
2024 Payments
$16,508
Companies
54
Transactions
1,735
Medicare Patients
21,545
Medicare Billing
$3.3M
Payment Breakdown by Category
Other$398,083 (89.1%)
Food & Beverage$37,268 (8.3%)
Consulting$5,801 (1.3%)
Travel$5,468 (1.2%)
Education$203.71 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $398,083 | 215 | 89.1% |
| Food and Beverage | $37,268 | 1,474 | 8.3% |
| Consulting Fee | $5,801 | 8 | 1.3% |
| Travel and Lodging | $5,468 | 19 | 1.2% |
| Education | $203.71 | 19 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $147,394 | 257 | $0 (2024) |
| Amarin Pharma Inc. | $132,221 | 160 | $0 (2023) |
| Lilly USA, LLC | $39,584 | 49 | $0 (2024) |
| Amgen Inc. | $34,789 | 157 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $32,510 | 68 | $0 (2021) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $27,943 | 96 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $17,849 | 81 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $2,503 | 174 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,696 | 124 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,641 | 133 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,508 | 86 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,010) |
| 2023 | $38,652 | 167 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,275) |
| 2022 | $34,752 | 185 | Boehringer Ingelheim Pharmaceuticals, Inc. ($28,419) |
| 2021 | $30,128 | 186 | Boehringer Ingelheim Pharmaceuticals, Inc. ($24,312) |
| 2020 | $49,936 | 216 | Amarin Pharma Inc. ($18,781) |
| 2019 | $110,698 | 307 | Amarin Pharma Inc. ($68,377) |
| 2018 | $87,538 | 309 | Amarin Pharma Inc. ($29,140) |
| 2017 | $78,612 | 279 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($22,408) |
All Payment Transactions
1,735 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Heart Failure | ||||||
| 12/12/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.98 | General |
| Category: Cardiovascular | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/22/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $880.00 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $30.31 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Cardiology | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $99.08 | General |
| Category: DIABETES | ||||||
| 10/25/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.59 | General |
| 10/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.64 | General |
| Category: Cardiovascular | ||||||
| 10/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: DIABETES | ||||||
| 10/08/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $32.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/04/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $24.28 | General |
| Category: Coronary | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/09/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.87 | General |
| Category: Cardiovascular | ||||||
| 08/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $34.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/27/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/23/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 5,164 | 9,208 | $2.1M | $690,792 |
| 2022 | 36 | 5,178 | 9,152 | $2.0M | $778,801 |
| 2021 | 36 | 5,769 | 9,964 | $2.5M | $992,871 |
| 2020 | 36 | 5,434 | 8,654 | $2.1M | $815,118 |
Total Patients
21,545
Total Services
36,978
Medicare Billing
$3.3M
Procedure Codes
162
All Medicare Procedures & Services
162 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 636 | 1,244 | $373,200 | $118,949 | 31.9% |
| 33285 | Insertion of heart rhythm monitor under skin | Office | 2023 | 22 | 22 | $187,000 | $80,243 | 42.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 182 | 184 | $174,800 | $66,449 | 38.0% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 99 | 813 | $174,795 | $46,563 | 26.6% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 182 | 368 | $73,600 | $42,933 | 58.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 225 | 234 | $175,500 | $35,982 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 192 | 242 | $84,700 | $35,332 | 41.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 190 | 341 | $68,200 | $33,374 | 48.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 222 | 487 | $85,225 | $31,689 | 37.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 122 | 496 | $49,600 | $20,489 | 41.3% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 25 | 25 | $37,500 | $17,560 | 46.8% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 99 | 815 | $61,125 | $16,279 | 26.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 111 | 114 | $42,750 | $16,256 | 38.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 684 | 1,099 | $65,940 | $12,816 | 19.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 68 | 68 | $27,200 | $11,689 | 43.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 201 | 203 | $62,930 | $11,161 | 17.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 72 | 72 | $32,400 | $10,604 | 32.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 189 | 196 | $68,600 | $9,975 | 14.5% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 22 | 22 | $55,000 | $9,735 | 17.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 88 | 90 | $27,000 | $9,663 | 35.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 826 | 1,010 | $30,300 | $6,674 | 22.0% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 42 | 42 | $16,800 | $6,195 | 36.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 78 | 241 | $12,050 | $5,448 | 45.2% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 20 | 20 | $14,000 | $4,910 | 35.1% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 77 | 238 | $11,900 | $4,225 | 35.5% |
About Dr. Robert Koch, DO
Dr. Robert Koch, DO is a Cardiovascular Disease healthcare provider based in Libertyville, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962497974.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Koch, DO has received a total of $446,823 in payments from pharmaceutical and medical device companies, with $16,508 received in 2024. These payments were reported across 1,735 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($398,083).
As a Medicare-enrolled provider, Koch has provided services to 21,545 Medicare beneficiaries, totaling 36,978 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 162 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Libertyville, IL
- Active Since 09/15/2005
- Last Updated 12/27/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1962497974
Products in Payments
- JARDIANCE (Drug) $177,062
- Vascepa (Drug) $132,221
- Livalo (Drug) $32,510
- Repatha (Biological) $31,586
- LifeVest (Device) $27,943
- FARXIGA (Drug) $17,099
- PRADAXA (Drug) $9,833
- Corlanor (Drug) $3,133
- XARELTO (Drug) $2,406
- ELIQUIS (Drug) $2,239
- ENTRESTO (Drug) $1,192
- BRILINTA (Drug) $589.92
- CHANTIX (Drug) $540.35
- LEQVIO (Drug) $449.11
- WATCHMAN (Device) $431.37
- VERQUVO (Drug) $377.42
- NEXLETOL (Drug) $360.47
- NORTHERA (Drug) $358.03
- Ozempic (Drug) $334.07
- PRALUENT (Drug) $304.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Libertyville
Fahd Jajeh, Md, MD
Cardiovascular Disease — Payments: $20,290
Cardiovascular Disease $20,290
Dr. Benjamin Rojas, D.o, D.O
Cardiovascular Disease — Payments: $20,087
Cardiovascular Disease $20,087
Maher Nahlawi, Md, MD
Cardiovascular Disease — Payments: $17,055
Cardiovascular Disease $17,055
Dr. Eric Kessler, M.d, M.D
Cardiovascular Disease — Payments: $12,926
Cardiovascular Disease $12,926
William Sanchez-Garcia, Md, MD
Cardiovascular Disease — Payments: $2,745
Cardiovascular Disease $2,745
Dr. Ray Helms, M.d, M.D
Cardiovascular Disease — Payments: $1,847
Cardiovascular Disease $1,847